NanO2 (perflenapent)

P1, N=18, Recruiting, NuvOx LLC | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=87, Active, not recruiting, NuvOx LLC | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

P1, N=18, Recruiting, NuvOx LLC | Not yet recruiting --> Recruiting

P2, N=172, Not yet recruiting, NHS Greater Glasgow and Clyde

P1, N=18, Not yet recruiting, NuvOx LLC | Initiation date: Oct 2024 --> Feb 2025

Our findings highlight the role of NaNO2 in enabling macrophage mimicry in TSCC cells through the CREB1-CD68 signaling pathway, which promotes lymphatic metastasis. Shedding light on drivers of lymphatic metastasis in TSCC and providing a new perspective on dietary strategies to improve outcomes of patients with TSCC.

P1, N=18, Not yet recruiting, NuvOx LLC

Together, our findings establish the potential of SCREE in mitigating the toxic effects of NaNO2 by modulating metabolic, inflammatory, and apoptosis. Together, this study underscores the promise of SCREE as a potential natural food detoxifying additive to counteract the harmful impacts of sodium nitrite.

Patients also received standard-of-care chemotherapy [temozolomide (TMZ)]. This study shows that DDFPe can be safely administered to patients, and it is the first-in-human study to show reversal of hypoxia in GBM as measured by TOLD MRI. This strategy is being used in a larger phase II/III trial which will hopefully show a survival benefit by adding DDFPe during the course of fractionated radiation and concurrent chemotherapy.